Based on the earnings call, it is clear that the company has experienced growth in all of its business units, including dental, animal health, medical, and technology. The company reported a 9.5% increase in net sales for the fourth quarter of 2016, and solid growth in both North America and international markets. Additionally, the company has reaffirmed its 2017 guidance, expecting a diluted EPS of $7.17 to $7.30 for the year.

The company has also implemented a share repurchase program, demonstrating its commitment to creating further value for shareholders and reflecting confidence in the long-term prospects of the business. The operating cash flow for the year exceeded goals, and the company continues to believe that its capital allocation strategy will drive increased shareholder value.

With the company's growth in sales and strong performance in all business units, it is recommended that investors consider an 'overweight' investment stance in the company based on its recent earnings call. The company's commitment to creating value for shareholders and its solid financial performance make it an attractive investment opportunity.